Drugs / PEP-3-KLH conjugate vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00626015 | Mar 2007 → Feb 2013 | brain cancer | John Sampson | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEP-3-KLH conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00626015 ↗ |
| Modality | Vaccine | “PEP-3-KLH conjugate vaccine” NCT00626015 ↗ |
| Target | EGFR | “epidermal growth factor receptor variant III (EGFRvIII) targeted peptide vaccination” PMID 22383993 ↗ Feb 2012 |